Aerie Pharmaceuticals IncのPEG
Aerie Pharmaceuticals IncのPEGは何ですか。
Aerie Pharmaceuticals IncのPEGは0.08です。
PEGの定義は何ですか。
PEGレシオは、株式のP / E比率を5年間の予想収益成長率で割ったものです。
The PEG ratio is calculated by dividing the P/E ratio by the company's expected earnings growth rate in the next 5 years. Since using just the P/E ratio would make high-growth companies appear overvalued relative to others, the PEG ratio is considered to be a convenient approximation. PEG is a widely employed indicator of a stock's possible true value.
Similar to P/E ratios, a lower PEG means that the stock is undervalued more. It is favored by many over the price/earnings ratio because it also accounts for growth. The PEG ratio of 1 is sometimes said to represent a fair trade-off between the values of cost and the values of growth, indicating that a stock is reasonably valued given the expected growth. A crude analysis suggests that companies with PEG values between 0 and 1 may provide higher returns. A PEG Ratio can also be a negative number if a stock's present income figure is negative, (negative earnings) or if future earnings are expected to drop (negative growth). PEG ratios calculated from negative present earnings are viewed with skepticism as almost meaningless, other than as an indication of high investment risk.
NASDAQのセクタHealth CareにおけるPEGの企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似のpeg
- CURO CorpのPEGは0.07です。
- West China CementのPEGは0.07です。
- Rare Earth Magnesium TechnologyのPEGは0.07です。
- Virgin Money Uk PlcのPEGは0.08です。
- Northern Oil and GasのPEGは0.08です。
- Northern Oil and GasのPEGは0.08です。
- Aerie Pharmaceuticals IncのPEGは0.08です。
- Delta Air LinesのPEGは0.08です。
- SM CoのPEGは0.08です。
- Helmerich & PayneのPEGは0.09です。
- Brighthouse IncのPEGは0.09です。
- SilverBow Resources IncのPEGは0.09です。
- EnerplusのPEGは0.09です。